Logo image of ALNOV.PA

NOVACYT (ALNOV.PA) Stock Fundamental Analysis

EPA:ALNOV - Euronext Paris - Matif - FR0010397232 - Common Stock - Currency: EUR

0.505  +0.01 (+1%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALNOV. ALNOV was compared to 73 industry peers in the Biotechnology industry. ALNOV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALNOV is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALNOV had negative earnings in the past year.
ALNOV had a negative operating cash flow in the past year.
In the past 5 years ALNOV reported 4 times negative net income.
In multiple years ALNOV reported negative operating cash flow during the last 5 years.
ALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

With a Return On Assets value of -37.87%, ALNOV perfoms like the industry average, outperforming 43.84% of the companies in the same industry.
The Return On Equity of ALNOV (-53.46%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.87%
ROE -53.46%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-1.97%
ROE(3y)-20.54%
ROE(5y)-3.98%
ROIC(3y)N/A
ROIC(5y)N/A
ALNOV.PA Yearly ROA, ROE, ROICALNOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

1.3 Margins

ALNOV has a better Gross Margin (153.78%) than 100.00% of its industry peers.
In the last couple of years the Gross Margin of ALNOV has declined.
ALNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 153.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.98%
GM growth 5Y-12.34%
ALNOV.PA Yearly Profit, Operating, Gross MarginsALNOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALNOV has about the same amount of shares outstanding.
ALNOV has more shares outstanding than it did 5 years ago.
ALNOV has a worse debt/assets ratio than last year.
ALNOV.PA Yearly Shares OutstandingALNOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALNOV.PA Yearly Total Debt VS Total AssetsALNOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 0.63, we must say that ALNOV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.63, ALNOV perfoms like the industry average, outperforming 52.05% of the companies in the same industry.
ALNOV has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALNOV (0.17) is better than 63.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 0.63
ROIC/WACCN/A
WACC7.38%
ALNOV.PA Yearly LT Debt VS Equity VS FCFALNOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

ALNOV has a Current Ratio of 4.04. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.04, ALNOV is in the better half of the industry, outperforming 75.34% of the companies in the same industry.
ALNOV has a Quick Ratio of 3.82. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
ALNOV's Quick ratio of 3.82 is fine compared to the rest of the industry. ALNOV outperforms 73.97% of its industry peers.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 3.82
ALNOV.PA Yearly Current Assets VS Current LiabilitesALNOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

ALNOV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.72%.
The Revenue has grown by 135.83% in the past year. This is a very strong growth!
The Revenue has been decreasing by -1.03% on average over the past years.
EPS 1Y (TTM)-47.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.53%
Revenue 1Y (TTM)135.83%
Revenue growth 3Y-65.3%
Revenue growth 5Y-1.03%
Sales Q2Q%209.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.21%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.47%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOV.PA Yearly Revenue VS EstimatesALNOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALNOV.PA Yearly EPS VS EstimatesALNOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 0 0.5 -0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1.91, the valuation of ALNOV can be described as very cheap.
Based on the Price/Forward Earnings ratio, ALNOV is valued cheaper than 98.63% of the companies in the same industry.
ALNOV is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.91
ALNOV.PA Price Earnings VS Forward Price EarningsALNOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNOV.PA Per share dataALNOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALNOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVACYT

EPA:ALNOV (6/18/2025, 7:00:00 PM)

0.505

+0.01 (+1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)09-25 2025-09-25
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap35.67M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.91
P/S 1.64
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)0.26
Fwd EY52.28%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.31
BVpS1.17
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.87%
ROE -53.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 153.78%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-1.97%
ROE(3y)-20.54%
ROE(5y)-3.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.98%
GM growth 5Y-12.34%
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.9%
Cap/Sales 7.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 3.82
Altman-Z 0.63
F-Score3
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)21.41%
Cap/Depr(5y)18.3%
Cap/Sales(3y)4.07%
Cap/Sales(5y)2.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.53%
EPS Next Y8.21%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)135.83%
Revenue growth 3Y-65.3%
Revenue growth 5Y-1.03%
Sales Q2Q%209.13%
Revenue Next Year48.47%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-224.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-208.32%
OCF growth 3YN/A
OCF growth 5YN/A